Literature DB >> 19191784

Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?

Basir Tareen1, Guilherme Godoy, Alex Sankin, Steve Temkin, Herbert Lepor, Samir S Taneja.   

Abstract

OBJECTIVE: To determine if biopsy characteristics can be used to identify men with unilateral prostate cancer on radical prostatectomy (RP) pathological specimens, thereby selecting candidates for hemi-ablative focal therapy. PATIENTS AND METHODS: Of 1458 men who had RP from January 2000 to June 2007, we identified 590 of 880 evaluable patients with unilateral disease on their preoperative biopsy. Charts were reviewed to record preoperative prostate-specific antigen (PSA) level, high-grade prostatic intraepithelial neoplasia (HGPIN), clinical stage, Gleason score, perineural invasion (PNI), prostate volume, number of positive cores, and percentage of positive cores. Final surgical pathology was evaluated for unilateral cancer. Univariate analysis was used (logistic regression method) to identify independent predictors of unilateral disease on the RP specimen. A subset analysis was done in men with low-risk disease, defined as clinical stage T1C, Gleason score <7 and a PSA level of <10 ng/mL.
RESULTS: Of 590 men with unilateral disease on biopsy, 163 (27.3%) had unilateral disease on the RP specimen. Pathological features, including HGPIN (P = 0.714), Gleason score (P > 0.608), PNI (P = 0.714), number of positive cores (P = 0.076), percentage of cores positive (P = 0.056), prostate volume (P = 0.285), and PSA level (P = 0.062) did not improve the prediction of unilateral disease. When men with unilateral cancer were further stratified to include only those with low-risk disease, 28.4% had unilateral disease on the RP specimen. None of the biopsy or clinical features evaluated were predictors of unilateral disease on the RP specimen.
CONCLUSION: Unilateral prostate cancer on biopsy predicts unilateral disease on RP pathology in only 27.6% of cases. The predictive ability is not improved by adding biopsy and clinical characteristics. Additional methods are needed to accurately identify men appropriate for focal therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191784     DOI: 10.1111/j.1464-410X.2009.08347.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

2.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

3.  Focal therapy for prostate cancer - where are we in 2011?

Authors:  Michael S Borofsky; Timothy Ito; Andrew B Rosenkrantz; Samir S Taneja
Journal:  Ther Adv Urol       Date:  2011-08

4.  PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.

Authors:  Thomas Hofner; Jesco Pfitzenmaier; Adel Alrabadi; Sascha Pahernik; Boris Hadaschik; Nina Wagener; Nenad Djakovic; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2010-12-31       Impact factor: 4.226

5.  Vascular targeted photodynamic therapy for localized prostate cancer.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2008

6.  Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 7.  Prostate focused ultrasound focal therapy--imaging for the future.

Authors:  Olivier Rouvière; Albert Gelet; Sébastien Crouzet; Jean-Yves Chapelon
Journal:  Nat Rev Clin Oncol       Date:  2012-08-21       Impact factor: 66.675

8.  Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings.

Authors:  Philip Quann; David F Jarrard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2010-03-30

9.  Management of Localized Prostate Cancer by Focal Transurethral Resection of Prostate Cancer: An Application of Radical TUR-PCa to Focal Therapy.

Authors:  Masaru Morita; Takeshi Matsuura
Journal:  Adv Urol       Date:  2012-05-22

10.  Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

Authors:  Samir S Taneja; James Bennett; Jonathan Coleman; Robert Grubb; Gerald Andriole; Robert E Reiter; Leonard Marks; Abdel-Rahmene Azzouzi; Mark Emberton
Journal:  J Urol       Date:  2016-06-09       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.